Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Starpharma Holdings Ltd

+ Add to Watchlist

SPHRY:US

5.3600 USD 0.1800 3.47%

As of 17:20:00 ET on 05/06/2015.

Snapshot for Starpharma Holdings Ltd (SPHRY)

Open: 5.3755 Day's Range: 5.3600 - 5.3800 Volume: 2,316
Previous Close: 5.1800 52wk Range: 3.2700 - 8.1500 1-Yr Rtn: -12.85%

Stock Chart for SPHRY

No chart data available.
  • SPHRY:US 5.3600
  • 1D
  • 1M
  • 1Y
5.1800
Interactive SPHRY Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SPHRY

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 171.06
Shares Outstanding (M) 31.91
30 Day Average Volume 1,972
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SPHRY

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)

Company Profile & Key Executives for SPHRY

Starpharma Holdings Limited is biotechnology company involved in the research, development and commercialization of dendrimer-based for pharmaceutical, life sciences and other applications. The Company's lead product in development is VivaGel, a microbicide gel for women, for the prevention and treatment of bacterial vaginosis adn a range of sexually transmitted diseases.

Robert Bain Thomas "Rob"ChairmanJacinth K Fairley "Jackie"CEO/Executive Director
Nigel J BaadeCFO/SecretaryTony EglezosVP:Business Development
More Company Profile & Key Executives for SPHRY

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil